Edition:
United States

People: Clovis Oncology Inc (CLVS.O)

CLVS.O on Nasdaq

65.80USD
17 Feb 2017
Change (% chg)

$4.43 (+7.22%)
Prev Close
$61.37
Open
$61.86
Day's High
$66.06
Day's Low
$61.50
Volume
2,950,242
Avg. Vol
2,222,963
52-wk High
$67.16
52-wk Low
$11.57

Barrett, M. James 

Dr. M. James E. Barrett, Ph.D., is an Independent Chairman of the Board of Clovis Oncology, Inc., since inception, April 20, 2009. He is the chairman of nominating and corporate governance committee. Since September 2001, he has served as a general partner of New Enterprise Associates Inc., a venture capital firm focusing on the healthcare, information technology and energy technology industries. From 1997 to 2001, Dr. Barrett served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, which he founded in 1997. Dr. Barrett serves on the boards of several pharmaceutical and biotechnology companies, including Blend Biosciences, Inc., Cardioxyl Pharmaceuticals, Inc., Galera Therapeutics, Inc., GlycoMimetics, Inc. (NASDAQ: GLYC), Loxo Oncology, Inc. (NASDAQ: LOXO), PhaseBio Pharmaceuticals, Inc., Predictive Biosciences, Inc., Psyadon Pharmaceuticals, Inc. (formerly known as Ruxton Pharmaceuticals, Inc.), Proteostasis Therapeutics, Inc. (NASDAQ: PTI), Roka Bioscience, Inc. (NASDAQ: ROKA), Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), and Zosano Pharma Corporation (NASDAQ: ZSAN), as well as continuing to serve as Chairman of Sensors for Medicine and Science. Dr. Barrett previously served on the board of, among others, Amicus Therapeutics, Inc. (NASDAQ: FOLD), Inhibitex, Inc. (NASDAQ: INHX) (acquired by Bristol-Myers Squibb (NASDAQ: BMY)), Targacept, Inc. (NASDAQ: TRGT), Pharmion Corporation, and YM Biosciences, Inc. (AMEX: YMI). Dr. Barrett received a Ph.D. in biochemistry from the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in chemistry from Boston College.

Basic Compensation

Total Annual Compensation, USD 79,938
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 562,399
Fiscal Year Total, USD 642,337

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --